Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use
- PMID: 26286531
- DOI: 10.1177/0004867415599846
Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use
Abstract
Objectives: Cannabis use is prevalent among people with first episode psychosis and the epidemiology of its use in early psychosis is unclear. We performed a meta-analysis of observational studies to determine; (1) the interval between age at initiation of cannabis use and age at onset of first episode psychosis, (2) the prevalence of cannabis use at time of first episode psychosis, and (3) the odds of continuing cannabis following treatment for first episode psychosis.
Data sources: Search of electronic databases MEDLINE, EMBASE, PsycINFO, Web of Science and CINAHL for English-language papers using search terms (psychosis OR schizophrenia) AND (cannabis OR marijuana) IN (title OR keyword OR abstract), current to October 2014.
Study selection: Studies were included if they reported on prevalence of current cannabis use in first episode psychosis cohorts. A total of 37 samples were included for meta-analysis.
Data extraction: Rates of cannabis use in each sample were extracted to determine prevalence estimates. The age at initiation of regular cannabis and age at onset of psychosis were used to determine the length of cannabis use preceding psychosis. Prevalence estimates at first episode psychosis and various time points of follow-up following first episode psychosis were analysed to determine odds ratio of continuing cannabis use. Data synthesis was performed using random-effects meta-analyses.
Results: The pooled estimate for the interval between initiation of regular cannabis use and age at onset of psychosis was 6.3 years (10 samples, standardised mean difference = 1.56, 95% confidence interval = [1.40, 1.72]). The estimated prevalence of cannabis use at first episode psychosis was 33.7% (35 samples, 95% confidence interval = [31%, 39%]). Odds of continued cannabis use between 6 months and 10 years following first episode psychosis was 0.56 (19 samples, 95% confidence interval = [0.40, 0.79]).
Keywords: Cannabis; epidemiology; first episode; meta-analysis; psychosis.
© The Royal Australian and New Zealand College of Psychiatrists 2015.
Similar articles
-
Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis.J Clin Psychiatry. 2012 Apr;73(4):468-75. doi: 10.4088/JCP.11r07222. J Clin Psychiatry. 2012. PMID: 22579146
-
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.Lancet Psychiatry. 2016 Oct;3(10):947-953. doi: 10.1016/S2215-0366(16)30188-2. Epub 2016 Aug 23. Lancet Psychiatry. 2016. PMID: 27567467
-
Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis.Psychol Med. 2016 Mar;46(4):673-81. doi: 10.1017/S0033291715002329. Epub 2015 Nov 16. Psychol Med. 2016. PMID: 26568030 Review.
-
Cannabis as a risk factor for psychosis: systematic review.J Psychopharmacol. 2005 Mar;19(2):187-94. doi: 10.1177/0269881105049040. J Psychopharmacol. 2005. PMID: 15871146
-
Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.Lancet Psychiatry. 2016 Mar;3(3):215-25. doi: 10.1016/S2215-0366(15)00363-6. Epub 2016 Jan 15. Lancet Psychiatry. 2016. PMID: 26777297 Review.
Cited by
-
Assessing Cannabis Use in People with Psychosis.Cannabis Cannabinoid Res. 2024 Feb;9(1):49-58. doi: 10.1089/can.2023.0032. Epub 2023 Nov 16. Cannabis Cannabinoid Res. 2024. PMID: 37971872 Free PMC article. Review.
-
Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals.EClinicalMedicine. 2023 Sep 8;64:102199. doi: 10.1016/j.eclinm.2023.102199. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37731936 Free PMC article.
-
Substance use Specificities in Women with Psychosis: A Critical Review.Curr Neuropharmacol. 2023;21(9):1953-1963. doi: 10.2174/1570159X21666221129113942. Curr Neuropharmacol. 2023. PMID: 36453494 Free PMC article. Review.
-
Acceptability of cannabidiol in patients with psychosis.Ther Adv Psychopharmacol. 2022 Oct 25;12:20451253221128445. doi: 10.1177/20451253221128445. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36312845 Free PMC article.
-
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study).Early Interv Psychiatry. 2023 Jun;17(6):597-607. doi: 10.1111/eip.13353. Epub 2022 Oct 4. Early Interv Psychiatry. 2023. PMID: 36196478 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical